“…13,14 Systemic therapy with thalidomide, lenalidomide, bortezomib, cytotoxic chemotherapy, rituximab or siltuximab (anti-interleukin-6 monoclonal antibody) may be considered for treatment of residual disease. 6,14 Post-operative adjunctive immunosuppression is, therefore, necessary for long periods of time and diverse agents have been used, despite their low efficacy. 3 These include oral corticosteroids, cyclosporin, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, IVIg, plasmapheresis and immunopheresis.…”